Discover and read the best of Twitter Threads about #DLBCL
Most recents (3)
Really chuffed to share our latest work from Sanjana Lab out in @nature today (nature.com/articles/s4158…).
We tested >12,000 genes to find positive regulators of T cell proliferation to be used for next-gen #immunotherapies.
A thread...
We tested >12,000 genes to find positive regulators of T cell proliferation to be used for next-gen #immunotherapies.
A thread...
(2/28) T cell therapies have shown the potential to cure patients from #cancer – but even in B cell cancers, relapses outnumber cures… One of the problems is limited T cell persistence. #celltherapy #CARTcell
(3/28) We wanted to find new genes (including genes never expressed in T cells) that could improve T cell persistence. Now, the question was: should we use #crispr activation or directly deliver target genes on a #lentivirus?
Delighted to share our new study nature.com/articles/s4158… introducing PhasED-Seq out today @NatureBiotech.
A fantastic collaboration from @StanfordMedicine led by Dave_Kurtz & Joanne Soo with @max_diehn to help transform #cancer interception & monitoring by improving #LiquidBiopsy #ctDNA detection of #MRD.
🎉CELEBRATION ALERT!! We reached 10K followers @NatureCancer - massive thank you to our wonderful community for the warm welcome! Given it is also 10 months of our online life, here are some of our best articles (although all are *fantastic*) #thread 1/n
#10atNatureCancer
#10atNatureCancer
January @NatureCancer: Nabel &co @SanofiUS develp #trispecific antibodies against CD3, CD28 and CD38, with preclinical efficacy and safety in humanized mice and NHPs 2/n
go.nature.com/30GlQyH
rdcu.be/b78Zr
#10atNatureCancer
go.nature.com/30GlQyH
rdcu.be/b78Zr
#10atNatureCancer
February @NatureCancer: Golub and Co @broadinstitute develop PRISM, a tool for non-oncology drug repurposing in #cancer 3/n
go.nature.com/36zCxQh
rdcu.be/b78ZE
#10atNatureCancer
go.nature.com/36zCxQh
rdcu.be/b78ZE
#10atNatureCancer
